Share Pharming among outperformers biotech companies

In the past years Pharming was a very good choice for investors. The stock was the past 5 years with a return of 386 percent one of the larger outperformers of her peer group. Shares of the peer group delivered the past 5 years a gain of at around 243 percent. Other strong winning shares of the sector are Pharming, Assembly Biosciences and Catalyst Pharmaceutical Partners. Among the outperformers in the sector are Assembly Biosciences, Catalyst Pharmaceutical Partners and Pharming.

Returns Pharming versus biotech sector

Returns stock Pharming over several periods, excluding dividend returns

Investors who invested in 2007 in the company's share now have a massive loss of 88 percent. Since 2012 the stock has a price gain of 386 percent. over the past 90 days the stock made a loss of 21 percent.

Core figures European biotech sector

The sector trades now at 4 times the earnings per share. The sector trades at 2,28 times the book value per share. Since 2012 the sector has plus of 243 percent and since 2007 a plus of 432 percent.

Over the current book year the total revenue will be 136,47 million euros (consensus estimates). This is quite more than 2017's revenue of 89,62 million euros.

Historical revenues and results Pharming plus estimates 2018

The analysts expect for 2018 a net profit of 22 million euros. For this year most of the analysts expect a profit per share of 4 cent. The PE-ratio therefore is 19.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,5 percent.

Latest estimates around 2 euros

Pharming's market capitalization is around 344,88 million euros. The Pharming stock was the past 12 months quite unstable. Since last January the stock is 39 percent lower. This year the stock price moved between 1 and 2 euro. Since 2008 the stock price is almost 88 percent lower.

Historical stock prices Pharming

On Friday the stock closed at 0,76 euros.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.